Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis
Authors
Keywords
Chemotherapy, Bevacizumab, Metastatic colorectal cancer, Systematic review, Meta-analysis
Journal
BMC CANCER
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-08-24
DOI
10.1186/s12885-016-2734-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial
- (2015) A. Passardi et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015
- (2015) E. Aranda et al. Clinical & Translational Oncology
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer
- (2015) Toshiaki Watanabe et al. International Journal of Clinical Oncology
- Value of bevacizumab in treatment of colorectal cancer: A meta-analysis
- (2015) Chun-Ying Qu WORLD JOURNAL OF GASTROENTEROLOGY
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2013) Alessandro Liberati ANNALS OF INTERNAL MEDICINE
- The Efficacy of Additional Bevacizumab to Cytotoxic Chemotherapy Regimens for the Treatment of Colorectal Cancer: An Updated Meta-Analysis for Randomized Trials
- (2013) Chao Lv et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
- (2013) David Cunningham et al. LANCET ONCOLOGY
- Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups
- (2012) Ligia Traldi Macedo et al. BMC CANCER
- XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
- (2012) Dimitrios Pectasides et al. BMC CANCER
- Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
- (2012) J Souglakos et al. BRITISH JOURNAL OF CANCER
- Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials
- (2012) C. Giessen et al. CLINICAL CANCER RESEARCH
- Clinical and Cost Effectiveness of Bevacizumab + FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea
- (2012) Eui-Kyung Lee et al. CLINICAL THERAPEUTICS
- First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
- (2012) E. Diaz-Rubio et al. ONCOLOGIST
- Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
- (2012) Zhong-Zhen Guan et al. Chinese Journal of Cancer
- Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C
- (2011) T. J. Price et al. ANNALS OF ONCOLOGY
- XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
- (2011) J Cassidy et al. BRITISH JOURNAL OF CANCER
- A systematic review of treatment guidelines for metastatic colorectal cancer
- (2011) M. S. Edwards et al. Colorectal Disease
- Impact ofKRASandBRAFGene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
- (2011) Timothy J. Price et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis
- (2011) Tobias Engel Ayer Botrel et al. LUNG CANCER
- Effectiveness and Safety of Bevacizumab for Unresectable Non-Small-Cell Lung Cancer
- (2010) Kun Yang et al. CLINICAL DRUG INVESTIGATION
- Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis
- (2010) Elena Galfrascoli et al. DIGESTIVE AND LIVER DISEASE
- Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan
- (2010) Takeru Shiroiwa et al. International Journal of Clinical Oncology
- Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
- (2010) Niall C. Tebbutt et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
- (2010) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study
- (2010) G.P. Stathopoulos et al. ONCOLOGY
- Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
- (2009) B. Nordlinger et al. ANNALS OF ONCOLOGY
- Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review
- (2009) S. Welch et al. ANNALS OF ONCOLOGY
- Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer
- (2009) Nadine A. Jackson et al. CANCER
- Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
- (2009) H. I. Hurwitz et al. ONCOLOGIST
- Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients
- (2009) Markus Moehler et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Treatment of the elderly colorectal cancer patient: SIOG expert recommendations
- (2008) D. Papamichael et al. ANNALS OF ONCOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started